Drug Trial Radar · NCT04279314
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Jan 29, 2020
Primary completion
Aug 19, 2022
Study completion Aug 19, 2022
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 5 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome
Conditions
- Rett Syndrome
Interventions
TrofinetideDrug
Trofinetide solution of 30-60 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Percentage of Subjects With Serious Adverse Events (SAEs), and Percentage of Subjects With Withdrawals Due to AEsTime frame: 40 Weeks Treatment Duration
- Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in ECGTime frame: 40 Weeks Treatment Duration
- Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Vital SignsTime frame: 40 Weeks Treatment Duration
- Subjects (N, %) With Post-baseline Potentially Clinically Important Changes in Body WeightTime frame: 40 Weeks Treatment Duration
- Subjects (N, %) With Post-baseline Potentially Clinically Important ChangesTime frame: 40 Weeks Treatment Duration
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Translational Genomics Research Institute (TGen)
Phoenix, Arizona
University of California, San Diego
La Jolla, California
UC Davis MIND Institute
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
Children Medical Services
Tampa, Florida
Emory Genetics Clinical Trial Center
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Kennedy Krieger Institute - Clinical Trials Unit
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota
Washington University School of Medicine, St. Louis Children's Hospital
St Louis, Missouri
Montefiore Medical Center, Children's Hospital at Montefiore
The Bronx, New York
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Greenwood Genetic Center
Greenwood, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Children's Hospital
Houston, Texas
Seattle Children's
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.